High-dose tamoxifen is not a feasible option in patients with relapsed or refractory multiple myeloma

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1439, 2004-01, pp. : 17-17

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bortezomib continues to demonstrate superiority over high-dose dexamethasone in patients with relapsed multiple myeloma

By  

Inpharma, Vol. 1, Iss. 1621, 2008-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Oblimersen feasible in relapsed multiple myeloma

By  

Inpharma, Vol. 1, Iss. 1489, 2005-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Carfilzomib: In Relapsed, or Relapsed and Refractory, Multiple Myeloma

By McCormack Paul L.  

Drugs, Vol. 72, Iss. 15, 2012-10 ,pp. : 2023-2032

Adis International

Access to resources Recommend Favorite

Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients

By Barbee Meagan S.   Nooka Ajay   Kaufman Jonathan L.   Kim Sungjin   Chen Zhengjia   Heffner Leonard T.   Lonial Sagar   Harvey R. Donald  

Cancer, Vol. 121, Iss. 6, 2015-03 ,pp. : 853-862

Blackwell Publishing

Access to resources Recommend Favorite

High-dose chemotherapy + stem cells for multiple myeloma

By  

Inpharma, Vol. 1, Iss. 1387, 2003-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite